Optimized Solid Tumor Next-Generation Sequencing (NGS) Panel: Clinical Impact of Unique Informative Content Beyond Commercial Assays
AMP 2025
A. Khanshour, M. Awobajo-Otesanya, M. Bhandari, C. Tang, Z. Wang, E. Ostman, H. Zheng, H. Yao, L. Li, M. Cantu, J. Xu, J. Park, J. SoRelle
Introduction
Comprehensive genomic profiling is critical in the
management of solid tumors, yet next-generation sequencing (NGS)
panel size does not always correlate with clinical utility. We evaluated the
performance of our in-house solid tumor NGS panel to identify
opportunities for strategic refinement and to compare its utility against
leading commercial assays. Methods: We conducted a retrospective
analysis of 2,085 solid tumor cases reported by the UT Southwestern
(UTSW) Clinical NGS Laboratory between December 2018 and April
- All cases were analyzed using our customized solid tumor NGS
panel targeting 1,516 genes. Standard bioinformatics pipelines and quality
control measures were applied. Genes were categorized based on their
reporting frequency and clinical informativeness, defined by the presence
of Tier I/II variants. The UTSW panel was benchmarked against 3
commercial assays – Illumina TSO500 (523 genes), Tempus xT (649
genes), and SOPHiA GENETICS Cancer Profiling Solution panel (480
genes) – to identify unique, shared, and underrepresented genes.
Results
A total of 308 genes of the UTSW panel were classified as
clinically informative, forming a strong foundation for streamlined testing
and potential panel optimization. Among them, 58 genes (19%) were
uniquely informative – absent from all 3 commercial assays. Of these, 20
genes are listed in the Cancer Gene Census in COSMIC database as
somatic cancer-associated genes. Notably, 12 of the 58 unique genes
(AFF3, AUTS2, BAZ2A, CAMTA1, CD44, DGKB, GTF2I, PRKCA, RGS7,
RPL22, RUNX2, and WHSC1) have well-established oncologic
associations, with Tier I/II variants identified in 10 internal cases. These
variants contributed additional diagnostic and/or prognostic value,
underscoring the relevance of these genes for the tumor types routinely
tested at the UTSW Clinical NGS Laboratory. Conclusions: Our study
demonstrates that the UTSW customized NGS solid tumor panel provides
substantial clinical value beyond what is captured by leading commercial
assays. The identification of 58 uniquely informative genes – many with
established oncologic relevance and documented Tier I/II variants –
highlights the importance of context-specific panel design. These findings
support the strategic refinement of genomic testing to prioritize clinically
actionable content, ultimately enhancing diagnostic precision and
personalized cancer care.
Related publications